<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337986</url>
  </required_header>
  <id_info>
    <org_study_id>Ampyra Vision 2011 RTN</org_study_id>
    <secondary_id>WU HRPO# : 201104126</secondary_id>
    <nct_id>NCT01337986</nct_id>
  </id_info>
  <brief_title>Ampyra for Optic Neuritis in MS</brief_title>
  <official_title>Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
      blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the
      hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery
      after optic neuritis from MS, will result in symptomatic improvement in visual function. The
      study will consist of one screening/baseline visit, one visit during treatment with active
      drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned
      to receive study medication or placebo for the first three weeks, followed by a two week
      wash-out, and then treatment reallocation for the latter three weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optic neuritis (ON) is the presenting feature of multiple sclerosis (MS) in 15% of cases, and
      occurs over the disease course in 50% of patients.1-3 Vision remains a major concern for MS
      patients, as visual dysfunction leads to lower quality of life.4-6 Despite the high
      prevalence of ON in MS, treatment and management options remain limited. Although intravenous
      glucocorticoids are employed to aid recovery of an acute episode of ON, no convincing
      evidence supports their efficacy in altering the degree of long-term recovery.7 Although some
      individuals with ON can have a dramatic recovery from blindness, ON often impairs visual
      function permanently. In the Optic Neuritis Treatment Trial, 63% reported that vision had not
      returned to normal after 6 months, and 20% had vision worse than 20/20 after 5 years of
      follow-up.8, 9 Visual impairment creates difficulties at home and work, leading to decreased
      independence and impaired mobility within the community. Visual dysfunction in combination
      with MS impairments within cerebellar and proprioceptive systems can be particularly
      disabling.

      Optic neuritis classically impairs one's ability to read print or a computer screen, to drive
      in bright or low light, and to appreciate colors and contrasts. Unfortunately, when optic
      neuritis results in lasting impairment, there are no pharmacologic therapies to restore
      vision. Low vision specialists may provide magnifying glasses, brighter lights, and advice to
      optimize the position of objects at home and in the workplace. Better treatment options are
      needed to improve visual function.

      Ampyra (dalfampridine) is a potassium-channel antagonist, with a mechanism-of-action to
      improve nerve conduction in demyelinated axons, resulting in an electrophysiologic and
      clinical benefit.10-22 Demyelinated axons within the anterior visual pathway would be a prime
      and ideal target to study the effects of Ampyra. In fact, Stefoski et al demonstrated visual
      function benefit in an open-label study of IV 4-aminopyridine in 12 subjects.21 The optic
      nerves are a well-defined white-matter tract, commonly affected in MS, and with clear
      clinical outcome measures. In addition, visual evoked potentials (VEPs) can be included
      within the study design as a secondary endpoint, to confirm improved nerve conduction.
      Because VEPs are such a precise, reliable, and accepted measure of demyelination, the
      anterior visual pathway is the ideal in vivo human system to study the electro-physiologic
      effects of a therapeutic such as Ampyra.

      Hypothesis 1: Dalfampridine treatment will improve visual function, measured by the 5% ETDRS
      contrast sensitivity chart, in subjects with long-term visual impairment secondary to optic
      neuritis from MS.

      Hypothesis 2: Dalfampridine treatment will reduce visual evoked potential P100 latency
      following remote optic neuritis.

      Hypothesis 3: Dalfampridine treatment will result in an improvement in secondary endpoints,
      including visual fields, high contrast visual acuity, color vision, and quality of life.

      The study will be conducted at the Department of Neurology and Neurosurgery, Washington
      University School of Medicine, St. Louis, the institution at which Dr. Naismith is based. The
      MS patients will come from the 1800 active MS patients in our clinic and the 3500 in the St.
      Louis area.

      Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
      blinded cross-over trial of dalfampridine of 8 weeks duration (Table 1). The study will test
      the hypothesis that dalfampridine, when administered to subjects with incomplete visual
      recovery after optic neuritis from MS, will result in symptomatic improvement in visual
      function. The study will consist of one screening/baseline visit, one visit during treatment
      with active drug, and one visit on placebo. After the baseline visit, subjects will be
      randomly assigned to receive study medication or placebo for the first three weeks, followed
      by a two week wash-out, and then treatment reallocation for the latter three weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Dalfampridine on visual function (contrast sensitivity).</measure>
    <time_frame>8 weeks</time_frame>
    <description>Dalfampridine treatment will improve visual function, measured by the 5% ETDRS contrast sensitivity chart, in subjects with long-term visual impairment secondary to optic neuritis from MS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dalfampridine reduce visual evoked potential P100 latency.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Dalfampridine treatment will reduce visual evoked potential P100 latency following remote optic neuritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dalfampridine improvement in other vision testing (acuity, color, and fields).</measure>
    <time_frame>8 weeks</time_frame>
    <description>Dalfampridine treatment will result in an improvement in visual fields, high contrast visual acuity, and color vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dalfampridine affect on quality of life.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Dalfampridine treatment will result in an improvement quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Group A: Dalfampridine/Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Placebo/Dalfampridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine/Placebo</intervention_name>
    <description>Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
    <arm_group_label>Group A: Dalfampridine/Placebo</arm_group_label>
    <other_name>Ampyra (R)</other_name>
    <other_name>Fampridine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/Dalfampridine</intervention_name>
    <description>Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
    <arm_group_label>Group B: Placebo/Dalfampridine</arm_group_label>
    <other_name>Ampyra (R)</other_name>
    <other_name>Fampridine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria are:

          1. At least one previous clinical episode of optic neuritis,

          2. the last episode of ON must have occurred at least 12 months prior to study entry,

          3. clinically definite MS, defined by the revised McDonald criteria, 23

          4. ages 18-70,

          5. visual acuity greater than or equal to 20/30

          6. must be able to read at least 2 of the 5 letters on the top line of the 5% ETDRS chart
             (logMAR 0.96) at 3 meters, 2 meters or 1 meter, and

          7. must have sufficient cognitive function to understand the consent process and to
             reliably perform all clinical assessments

        Exclusion criteria are:

          1. Any ophthalmologic condition, other than ON, which can affect vision, including
             nystagmus in primary position of gaze,

          2. history of seizures or spells with altered level of consciousness,

          3. pregnancy or breast feeding,

          4. an MS exacerbation or use of glucocorticoids within 3 months of entry,

          5. a history of moderate to severe renal insufficiency,

          6. previous use of 4-aminopyridine, in any formulation, in the prior 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert T Naismith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University (John L. Trotter MS Center)</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neuro.wustl.edu/research/mscenter/</url>
    <description>John L. Trotter MS Center, Washington University School of Medicine &amp; Barnes Jewish Hospital</description>
  </link>
  <reference>
    <citation>Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005 Feb;4(2):111-21. Review.</citation>
    <PMID>15664543</PMID>
  </reference>
  <reference>
    <citation>Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005 Jun;139(6):1101-8. Review.</citation>
    <PMID>15953446</PMID>
  </reference>
  <reference>
    <citation>Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006 Mar 23;354(12):1273-80. Review.</citation>
    <PMID>16554529</PMID>
  </reference>
  <reference>
    <citation>Ma SL, Shea JA, Galetta SL, Jacobs DA, Markowitz CE, Maguire MG, Balcer LJ. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol. 2002 May;133(5):686-92.</citation>
    <PMID>11992867</PMID>
  </reference>
  <reference>
    <citation>Noble J, Forooghian F, Sproule M, Westall C, O'Connor P. Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients. Am J Ophthalmol. 2006 Sep;142(3):464-8.</citation>
    <PMID>16935592</PMID>
  </reference>
  <reference>
    <citation>Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, Nano-Schiavi ML, Cutter GR, Maguire MG, Balcer LJ. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):767-72. doi: 10.1136/jnnp.2008.165449. Epub 2009 Feb 23.</citation>
    <PMID>19240050</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581-8.</citation>
    <PMID>1734247</PMID>
  </reference>
  <reference>
    <citation>Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol. 1997 Dec;115(12):1545-52.</citation>
    <PMID>9400788</PMID>
  </reference>
  <reference>
    <citation>Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol. 1997 Mar;17(1):18-23; quiz 24-8.</citation>
    <PMID>9093956</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.</citation>
    <PMID>19249634</PMID>
  </reference>
  <reference>
    <citation>Fujihara K, Miyoshi T. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci. 1998 Jul 15;159(1):102-6.</citation>
    <PMID>9700711</PMID>
  </reference>
  <reference>
    <citation>Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997 Apr;48(4):817-21.</citation>
    <PMID>9109861</PMID>
  </reference>
  <reference>
    <citation>Davis FA, Stefoski D, Quandt FN. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol. 1995 May;37(5):684.</citation>
    <PMID>7755367</PMID>
  </reference>
  <reference>
    <citation>Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 1994 Jun;44(6):1054-9.</citation>
    <PMID>8208399</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 1994 Mar;51(3):292-6.</citation>
    <PMID>8129642</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, Bertelsmann FW, Koetsier JC. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci. 1993 Jun;116(2):220-6.</citation>
    <PMID>8336169</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992 Aug;32(2):123-30.</citation>
    <PMID>1510353</PMID>
  </reference>
  <reference>
    <citation>Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991 Sep;41(9):1344-8.</citation>
    <PMID>1891078</PMID>
  </reference>
  <reference>
    <citation>Polman CH, van Diemen HA, van Dongen MM, Koetsier JC, van Loenen AC, van Walbeek HK. 4-Aminopyridine in multiple sclerosis. Ann Neurol. 1990 Oct;28(4):589.</citation>
    <PMID>2082971</PMID>
  </reference>
  <reference>
    <citation>Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1990 Feb;27(2):186-92.</citation>
    <PMID>2317014</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the &quot;McDonald Criteria&quot;. Ann Neurol. 2005 Dec;58(6):840-6. Review.</citation>
    <PMID>16283615</PMID>
  </reference>
  <reference>
    <citation>Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983 Aug-Sep;60(3):353-62.</citation>
    <PMID>6631441</PMID>
  </reference>
  <reference>
    <citation>Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clin Ther. 2009 Oct;31(10):2206-14. doi: 10.1016/j.clinthera.2009.10.008.</citation>
    <PMID>19922891</PMID>
  </reference>
  <reference>
    <citation>Vollmer T, Blight AR, Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther. 2009 Oct;31(10):2215-23. doi: 10.1016/j.clinthera.2009.10.007.</citation>
    <PMID>19922892</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Ruchman MC, Savino PJ, Schatz NJ. Contrast sensitivity measurements in acute and resolved optic neuritis. Br J Ophthalmol. 1984 Oct;68(10):756-9.</citation>
    <PMID>6477856</PMID>
  </reference>
  <reference>
    <citation>Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996 May;121(5):547-53.</citation>
    <PMID>8610798</PMID>
  </reference>
  <reference>
    <citation>Farnsworth D. The Farnsworth-Munsell 100-hue and dichotomous tests for color vision. J Opt Soc Am 1943;33:568-574.</citation>
  </reference>
  <reference>
    <citation>Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, Song SK, Cross AH. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009 Mar 24;72(12):1077-82. doi: 10.1212/01.wnl.0000345042.53843.d5.</citation>
    <PMID>19307541</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Tutlam NT, Xu J, Shepherd JB, Klawiter EC, Song SK, Cross AH. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology. 2009 Jul 7;73(1):46-52. doi: 10.1212/WNL.0b013e3181aaea32.</citation>
    <PMID>19564583</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Xu J, Tutlam NT, Trinkaus K, Cross AH, Song SK. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology. 2010 May 25;74(21):1702-10. doi: 10.1212/WNL.0b013e3181e0434d.</citation>
    <PMID>20498438</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Xu J, Tutlam NT, Scully PT, Trinkaus K, Snyder AZ, Song SK, Cross AH. Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology. 2010 May 25;74(21):1694-701. doi: 10.1212/WNL.0b013e3181e042c4. Erratum in: Neurology. 2010 Sep 7;75(10):938.</citation>
    <PMID>20498437</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Xu J, Tutlam NT, Snyder A, Benzinger T, Shimony J, Shepherd J, Trinkaus K, Cross AH, Song SK. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology. 2009 Feb 17;72(7):589-94. doi: 10.1212/01.wnl.0000335766.22758.cd. Epub 2008 Dec 10.</citation>
    <PMID>19073948</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Shepherd JB, Weihl CC, Tutlam NT, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol. 2009 Aug;66(8):1025-7. doi: 10.1001/archneurol.2009.70.</citation>
    <PMID>19667226</PMID>
  </reference>
  <reference>
    <citation>Vanden Bosch ME, Wall M. Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method. Eye (Lond). 1997;11 ( Pt 3):411-7.</citation>
    <PMID>9373488</PMID>
  </reference>
  <reference>
    <citation>Acorda Therapeutics. AMPRYA package insert (2010).</citation>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Naismith</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Ampyra</keyword>
  <keyword>Dalfampridine</keyword>
  <keyword>Fampridine</keyword>
  <keyword>Remote Optic Neuritis</keyword>
  <keyword>Contrast Sensitivity</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 4, 2016</submitted>
    <returned>June 17, 2016</returned>
    <submitted>February 14, 2018</submitted>
    <returned>March 15, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

